The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

DKK 2016 | Achieving a definitive treatment for chronic lymphocytic leukemia

Name: Achieving a definitive treatment for chronic lymphocytic leukemia
Uploaded: 2016-02-25T00:00:00Z
Duration: 1 min 43 s
Description: At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses the rapidly changing treatment landscape of chronic lymphocytic leukemia, including the development of new venetoclax-based combinations with improved treatment efficacy.

Michael Hallek • 25 Feb 2016

DKK 2016

Chronic Lymphocytic Leukemia Venetoclax

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses the rapidly changing treatment landscape of chronic lymphocytic leukemia, including the development of new venetoclax-based combinations with improved treatment efficacy.